Molecular rules underpinning enhanced affinity binding of human T cell receptors engineered 2 for immunotherapy by Crean, Rory M et al.
                          Crean, R. M., MacLachlan, B. J., Madura, F., Whalley, T., Rizkallah,
P. J., Holland, C. J., McMurran, C., Harper, S., Godkin, A., Sewell, A.
K., Pudney, C. R., Van Der Kamp, M. W., & Cole, D. K. (2020).
Molecular rules underpinning enhanced affinity binding of human T
cell receptors engineered 2 for immunotherapy. Molecular Therapy,
18, 443-456. https://doi.org/10.1016/j.omto.2020.07.008
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1016/j.omto.2020.07.008
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier at
https://www.sciencedirect.com/science/article/pii/S2372770520301121. Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Original ArticleMolecular Rules Underpinning Enhanced
Affinity Binding of Human T Cell
Receptors Engineered for Immunotherapy
Rory M. Crean,1,2 Bruce J. MacLachlan,3,8 Florian Madura,3 Thomas Whalley,3 Pierre J. Rizkallah,3
Christopher J. Holland,4 Catriona McMurran,4 Stephen Harper,4 Andrew Godkin,3 Andrew K. Sewell,3
Christopher R. Pudney,1,5 Marc W. van der Kamp,6,7 and David K. Cole3,4,7
1Department of Biology and Biochemistry, University of Bath, Bath, BA2 7AY, UK; 2Doctoral Training Centre in Sustainable Chemical Technologies, University of Bath,
Bath, BA2 7AY, UK; 3Division of Infection & Immunity, Cardiff University, Cardiff, CF14 4XN, UK; 4Immunocore, Ltd., Abingdon, OX14 4RY, UK; 5Centre for Therapeutic
Innovation, University of Bath, Bath, BA2 7AY, UK; 6School of Biochemistry, University of Bristol, Biomedical Sciences Building, University Walk, Bristol, BS8 1TD, UKReceived 15 July 2020; accepted 27 July 2020;
https://doi.org/10.1016/j.omto.2020.07.008.
7These authors contributed equally to this work.
8Present address: Monash Biomedicine Discovery Institute, 19 Innovation Walk,
Clayton, VIC 3800, Australia
Correspondence: Marc W. van der Kamp, School of Biochemistry, University of
Bristol, Biomedical Sciences Building, University Walk, Bristol, BS8 1TD, UK.
E-mail: marc.vanderkamp@bristol.ac.uk
Correspondence: David K. Cole, Immunocore, Ltd., Abingdon, OX14 4RY, UK.
E-mail: david.cole@immunocore.comImmuno-oncology approaches that utilize T cell receptors
(TCRs) are becoming highly attractive because of their poten-
tial to target virtually all cellular proteins, including cancer-
specific epitopes, via the recognition of peptide-human leuko-
cyte antigen (pHLA) complexes presented at the cell surface.
However, because natural TCRs generally recognize cancer-
derived pHLAs with very weak affinities, efforts have been
made to enhance their binding strength, in some cases by
several million-fold. In this study, we investigated the mecha-
nisms underpinning human TCR affinity enhancement by
comparing the crystal structures of engineered enhanced affin-
ity TCRs with those of their wild-type progenitors. Addition-
ally, we performed molecular dynamics simulations to better
understand the energetic mechanisms driving the affinity en-
hancements. These data demonstrate that supra-physiological
binding affinities can be achieved without altering native
TCR-pHLA binding modes via relatively subtle modifications
to the interface contacts, often driven through the addition
of buried hydrophobic residues. Individual energetic compo-
nents of the TCR-pHLA interaction governing affinity en-
hancements were distinct and highly variable for each TCR,
often resulting from additive, or knock-on, effects beyond the
mutated residues. This comprehensive analysis of affinity-
enhanced TCRs has important implications for the future
rational design of engineered TCRs as efficacious and safe
drugs for cancer treatment.
INTRODUCTION
Recent advances in immuno-oncology (IO) have revolutionized the
treatment of some cancers by harnessing and redirecting T cells
against tumors. These successes are driving new areas of IO develop-
ment, including exploiting T cell receptor (TCR) recognition of short
antigenic peptide fragments presented at the cell surface by peptide-
human leukocyte antigens (pHLAs). These peptide fragments repre-
sent virtually all cellular proteins, allowing TCRs to access a much
larger pool of potential therapeutic targets than monoclonal anti-Molecular Therapy
This is an open access article under tbodies (mAbs), which primarily bind to extracellular antigens.1
This advantage has encouraged the development of soluble engi-
neered TCRs as therapeutics for viral and cancerous diseases.2–4 Sol-
uble TCRs have been designed as bispecific T cell engagers by
coupling with a T cell-activating antibody domain.5 This approach
of utilizing a soluble bispecific TCR to target cancer has been shown
to induce tumor regression in mice,6 and clinical trials are currently
under way for multiple diseases.
To achieve high sensitivity as a soluble receptor, mAbs undergo a nat-
ural process of somatic hypermutation to generate affinities for their
target antigens in the nanomolar to picomolar range. However, natu-
rally occurring TCRs are selected in the thymus to bind pHLAs with
relatively weak affinities (micromolar) and short half-lives (sec-
onds).7,8 TCRs that recognize cancer-derived pHLAs are at the
weaker end of the TCR-affinity scale,9 reflecting a further disadvan-
tage in their use to drive functional T cell responses against cancer.
Although it is not fully understood why TCRs are selected with these
binding characteristics, published evidence has demonstrated an
optimal TCR affinity window for T cell triggering,10–12 and that pep-
tide binding must be degenerate (i.e., TCRs must be able to function-
ally bind to many thousands of different peptides) in order to provide
immune coverage against all possible foreign antigens, while remain-
ing tolerant to self-antigens.13–16 Finally, weak TCR affinity may
enable T cells to rapidly disengage from target cells to allow them
to effectively penetrate tissues. This may contribute to the observation: Oncolytics Vol. 18 September 2020 Crown Copyright ª 2020 443
he CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1. Structural Analyses of all TCR-pHLAs Complexes under Investigation
TCR-pHLA TCR PDB KD (nM) On-Rate (M
1s1) Off-Rate (s1) Crossing Angle () SC
1G4-HLA-A*0201-SLL
wild-type 2BNR59 13,300 12,000 0.049 69.4 0.71
1G4_c5c1 2PYE28 81.6 17,800 0.0015 65.4 0.77
1G4_c49c50 2F533 1 180,000 0.00024 65.9 0.77
1G4_c58c61 2P5E28 0.048 570,000 0.00003 66.3 0.76
1G4_c58c62 2P5W28 nm nm 0.00003 65.7 0.78
DMF5-HLA-A*0201-ELA
wild-type 3QDG60 29,000 nm nm 33.3 0.65
DMF5_YW 4L3E23 24 nm nm 31.7 0.64
MEL5-HLA-A*0201-ELA
wild-type 3HG147 18,000 nm nm 47.6 0.64
MEL5_a24b17 4JFF34 0.6 179,000 0.0001 42.2 0.66
MEL5-HLA-A*0201-EAA
wild-type 4QOK61 8,400 nm nm 46.9 0.64
MEL5_a24b17 6TMO 0.75 280,000 0.00021 42.6 0.67
MEL5-HLA-A*0201-AAG
wild-type 6EQA62 14,200 nm nm 48.0 0.57
MEL5_a24b17 6EQB62 26.2 74,000 0.0019 42.3 0.71
A6-HLA-A*0201-LLF
wild-type 1AO763 3,200 23,000 0.074 33.5 0.63
A6_c134 4FTV27 4 45,000 0.00018 32.9 0.74
ILA1-HLA-A*0201-ILA
wild-type 5MEN16 34,000 3,490 0.13 39.8 0.64
ILA1_a1b1 4MNQ29 2 80,000 0.00016 42.1 0.57
Surface complementarity (SC) was determined using ePISA. KD, affinity dissociation constant; nm, not measured
Molecular Therapy: Oncolyticsthat stronger affinity chimeric antigen receptor (CAR)-T cells have a
limited ability to penetrate solid tumors.17 This thymically selected
balance between functionality and self-tolerance is also likely reflected
in the relatively conserved binding mode that has been observed for
the majority of TCR-pHLA complexes, which places the TCR diago-
nally over the center of the pHLA peptide-binding groove, enabling a
broad contact interface with both the peptide and HLA surface.
The natural weak affinity of TCRs imposes limitations on their use as
soluble therapeutics. Thus, in parallel with protein engineering stra-
tegies that have been used to generate therapeutic antibodies18 and
other therapeutic protein molecules,19 a number of approaches
focused on introducing affinity-enhancing mutations within the six
complementarity determining region (CDR) loops that comprise
the TCR binding site,3,20–25 or residues within the variable domain
interface, have been used.26 These mutations are designed to improve
the binding characteristics of the TCR-pHLA interaction, with the
intention of maintaining native characteristics, such as self-tolerance,
that are selected naturally during thymic selection.
In this study, we explored the fundamental mechanisms that under-
pin the interactions between engineered affinity-enhanced human
TCRs (aeTCRs) with pHLAs. With many possible mechanisms avail-
able for affinity enhancement (such as improved electrostatics, burial
of hydrophobic residues, expulsion of unfavorable water molecules,
and a reduction in the entropic cost of solute binding by rigidification
of the protein), the identification of principles by which TCRs can be
affinity enhanced, yet retain their native binding characteristics,
would be beneficial for the rational design of antigen-selective thera-444 Molecular Therapy: Oncolytics Vol. 18 September 2020peutic TCRs. We compared the structures of wild-type (WT) and
multiple aeTCRs specific for for distinct cancer-derived pHLAs and
one virally-derived pHLA. In addition, we performed molecular dy-
namics (MD) simulations and binding free energy calculations to
determine the energetic mechanisms driving affinity enhancement.
These data reveal new insights into the flexibility of the native
TCR-pHLA complex and demonstrate that this interaction is globally
compatible with large affinity enhancements without major recon-
struction of the binding interface. These findings have important im-
plications for our understanding of the basic principles that govern
thymic selection of “weak”-affinity natural TCRs, and for the develop-
ment of in silico rational design approaches for therapeutic aeTCRs.
RESULTS
aeTCRs Show Preservation of the WT Binding Mode
We analyzed the crystal structures of all published structures of TCR-
pHLA complexes where there exists a WT and an enhanced affinity
version of the same TCR (Table 1), and further solved the structure
of an enhanced affinity version of the MEL5 TCR (MEL5_a24b17
aeTCR) in complex with human leukocyte antigen (HLA)-A*0201-
EAAGIGILTV (A2-EAA) at 2.1 Å resolution (Table S1). Each of
the aeTCRs were previously generated through directed evolution ap-
proaches by positive selection on capacity to bind pHLA antigen,
except for DMF5_YW, which was affinity enhanced in silico.
We directly compared their overall binding geometry (crossing
angle, shape complementarity [SC], positions of the CDR loops)
and total contacts (Figure 1). Overall, and in line with previously
published findings,16,27–29 all aeTCRs bound their cognate pHLA
Figure 1. Structural Comparison of Overall Binding Modes of Affinity Enhanced and Wild-Type TCR-pHLA Complexes Shows Virtually Identical
Conformations
(A–F) Left: structural overlay of wild-type (WT) TCR-pHLA complexes versus affinity-enhanced (ae)TCR-pHLA complexes. TCR and HLA are shown as cartoon and peptide is
shown as stick representation. Right top: overlay of CDR loop positions of WT and aeTCRs. Backbone locations of each CDR loop shown as line representation. In each
panel, the WT TCR complex structure is in grayscale and the aeTCR complex structure is colored by chain: TCRa, blue; TCRb, green; HLA, dark gray; b2m, light gray. Right
bottom: TCR crossing angle of WT TCR-pHLA complexes versus aeTCR-pHLA complexes. pHLA is shown as surface representation (gray). TCRa (blue) and TCRb (green)
centroid locations of aeTCR structure are shown as spheres. (A) 1G4 TCR and multiple aeTCR variants in complex with HLA-A*0201-SLLMWITQC. (B) DMF5 TCR and
aeTCR variant DMF5_YW in complex with HLA-A*0201-ELAGIGILTV. (C) MEL5 TCR and aeTCR variant MEL5_a24b17 in complex with HLA-A*0201-ELAGIGILTV. (D) MEL5
TCR and aeTCR variant MEL5_a24b17 in complex with HLA-A*0201-EAAGIGILTV. (E) A6 TCR and aeTCR variant A6_c134 in complex with HLA-A*0201-LLFGYPVYV. (F)
ILA1 TCR and aeTCR variant ILA1_a1b1 in complex with HLA-A*0201-ILAKFLHWL.
www.moleculartherapy.orgwith virtually identical crossing angles and CDR loop positions
compared to their WT progenitor TCRs (Figures 1A–1F). We also
compared the binding footprint (in terms of the TCR position
from the center of the pHLA, toward either the N or C terminus
of the peptide, or the a1 or a2 helices of the HLA) of the aeTCRs
to all published TCR-pHLA complexes (Figure S1). The aeTCRs
were all within the normal distribution of known TCR-pHLA com-
plexes for both parameters. Most of the aeTCRs demonstrated
slightly increased SC, in line with their increases in affinity, butthis metric was not predictive of overall affinity gains (Table 1).
For example, an enhanced affinity version of the 1G4 TCR
(1G4_c58c61), which underwent the largest affinity gain compared
to its WT TCR progenitor (300,000-fold), demonstrated one of
the smallest gains in favorable SC compared to other aeTCRs.
aeTCRs Generally Form Additional Contacts with HLA
Assessment of the number of additional contacts formed between
the aeTCRs and the pHLA from the structural analysisMolecular Therapy: Oncolytics Vol. 18 September 2020 445
Figure 2. Differences in the Average Number of Contacts Formed during pHLA Engagement of WT TCRs versus aeTCRs
(A) Difference (D) in the number of contacts betweenWT TCRs and aeTCRs segregated by contact type analyzed using crystal structures. Boxplots represent median (middle
line), interquartile ranges Q1 (box lower) and Q3 (box upper), Q1-1.5*IQR (lower whisker), and Q3+1.5*IQR (upper whisker). Individual scatter points of each TCR are overlaid
and colored by the TCR-pHLA system-indicated inset. vdW, van der Waals (%4.0 Å); HBs, hydrogen bonds (%3.4 Å); SBs, salt bridges (%3.4 Å). (B) Difference in the
number of contacts between WT and aeTCRs from crystal structures segregated by contacts to HLA or peptide atoms or both (total). (C) Surface plots of the pHLA (peptide
atoms shown as spheres) with each structure color mapped according the average number of vdWs contacts formed between the given residue and the TCR during the
course of MD simulations. Color mapping was performed from white (no contacts) through yellow and orange to red (highest number of contacts observed for each of
the pairs of TCR-pHLAs studied). All pHLA structures are shown in the same orientation, such that the peptide N terminus is left, and the C terminus is right. TCR residues
contributing substantially to new contacts are labeled in black and indicated with black lines. Corresponding peptide or HLA residues are labeled in light blue. For brevity,
only one 1G4 aeTCR is shown; all others are shown in Figure S2. Note that (A) and (B) were generated from crystal structure analysis, while (C) was generated from MD
simulation data.
Molecular Therapy: Oncolyticsdemonstrated a modest increase in the total number of van der
Waals (vdWs) contacts and hydrogen bonds (HBs) for most com-
plexes (Figures 2A and 2B). Although most aeTCRs demonstrated
an increase in the total number of vdWs interactions, the 1G4
aeTCRs had virtually the same, or in one case lower, numbers
of vdWs contacts compared to the WT 1G4 TCR (Figure 2A).
We observed a similar average number of HBs, and a lower
average number of salt bridges (SBs) for the aeTCRs. aeTCRs
exhibited a trend toward increases in new contacts to HLA resi-
dues as opposed to the peptide residues (Figure 2B); except for
the A6_c134 aeTCR, which was the only TCR to make new con-
tacts with peptide residues. In most cases, this was driven by mu-446 Molecular Therapy: Oncolytics Vol. 18 September 2020tations that increased the size and hydrophobicity of the TCR
paratope.
To further unpick the contribution of each introduced mutation to
the binding interface, we turned to MD simulations (Tables S2 and
S3), performing 10 replicas of 100 ns each in both their apo and
pHLA-bound forms (totaling 22 ms of MD simulation). The use of
many independent replicas (such as the 10 performed here) is impor-
tant for obtaining reliable and reproducible results.30 This enabled
insight into how the number of contacts between the TCR and
pHLA changed over time (Figure 2C; Figures S1C–S1E and S2; Tables
S4–S7), rather than relying on static images generated from crystal
www.moleculartherapy.orgstructures alone. Overall, our findings were consistent compared to
the crystal structures (Figure 2A), with small increases in both the
average number of HBs and vdWs contacts for the MEL5 and
DMF5 aeTCRs, and no clear relationship between affinity and the
number of contacts for the 1G4 aeTCRs. This is consistent with pre-
vious findings that there is poor correlation between number of con-
tacts and affinity.31 For the A6_c134 TCR, although our MD simula-
tions suggested a smaller increase in the average number of contacts
compared to the analysis of the crystal structure, increases were
observed in the region of the HLA and peptide adjacent to the modi-
fied residues in the A6_c134 TCR CDR3b loop (Table S7).
To measure the extent to which contacts to individual pHLA residues
were preserved upon affinity enhancement, we calculated the total
average number of HBs and vdWs contacts formed between the
TCR and each pHLA residue. Of the 10 pHLA residues most con-
tacted by the 1G4 TCR (as defined by either HBs or vdWs contacts),
at least 8 were preserved for all aeTCR variants (Tables S4 and S5). For
both the DMF5 and A6 TCRs, the aeTCR variants preserved at least 9
of the top 10WT TCR contacts, while for the MEL5 TCR, 7 of the top
10 WT contacts were preserved (Tables S6 and S7). These results are
consistent with the aeTCRs preserving a native TCR-pHLA binding
footprint, combined with increases in contacts to existing as well as
new pHLA residues (Figure 2C).
We also applied our MD simulations to determine how the average
buried solvent-accessible surface area (BSASA) differed for all TCR-
pHLA complexes (Figure S1E). While the DMF5- and MEL5-derived
aeTCRs showed an increase in the BSASA, the A6- and 1G4-derived
aeTCRs showed no significant change.
Energetic Hotspots Are Largely Preserved during the Course of
Affinity Enhancement
To further assess how mutations affected the affinity between the
TCR and pHLA, we performed binding free energy calculations using
the molecular mechanics generalized born surface area (MMGBSA)
method.32 This approach uses MD simulations to sample conforma-
tions of the complex, receptor, and ligand, and subjects these snap-
shots to an empirical calculation to estimate the binding free energy
(DG). We note that this approach should not be relied on for absolute
binding affinities, and instead should be used to predict relative bind-
ing affinities among similar systems, as we have done here.33 Compar-
ison of our calculatedDDG values with the experimentally derived re-
sults from SPR experiments3,23,27–29,34 showed that the differences in
affinity between the aeTCRs and their WT progenitor TCRs were
identified correctly (Figure 3A).
Decomposing the calculated binding energies onto a per residue level
can indicate which interactions are the main drivers for the increased
binding affinity. We note that these per residue decomposition values
do not directly relate to a possible experimental measurement and
should be used in a more qualitative manner to identify key favor-
able/unfavorable residues/interactions across the binding interface.
While our primary focus was on the binding differences betweenaeTCRs and their WT progenitor TCRs (i.e., DDG), we showed that
the energetic hotspots across the TCR-pHLA interface were largely
conserved upon affinity enhancements (Figure 3B; Figure S3), in
line with the observation that the number and types of contacts
were largely maintained (Figures 1 and 2).
Decomposition of the Calculated Binding Energies Reveal the
Molecular Basis for Affinity Enhancement
For the examples described in this study, the mutated residues were
located in one of the six CDR loops, or the two hypervariable 4
(HV4) loops, which comprise the TCR paratope. However, most of
the residues selected during the aeTCR generation do not make direct
antigen contacts. Thus, we hypothesized that these residues may exert
their effects indirectly, instead optimizing the residues that make
direct contact with the pHLA. We therefore calculated the changes
in the per residue contributions to the TCR-pHLA binding affinity
upon affinity enhancement (i.e., DDG, Figures 4 and 5) to further un-
derstand how each of these mutations modified TCR-pHLA affinities.
This analysis indicated that the 1G4 aeTCR loop mutations had a
largely additive effect on TCR-pHLA binding; i.e., the contribution
of mutations in one loop was not affected by mutations in other loops
(Figure 4A). For the 1G4 aeTCR a chains, the two different mutations
introduced into the CDR2a loop (Figures 4B and 4C) both appeared
to improve affinity via the same mechanism: large hydrophobic (and
aromatic) groups were introduced in locations where they can be
effectively buried at the interface (either S53W, or S52F and S53W).
The G97D mutation in the CDR3a loop was predicted to be unfavor-
able for all three cases in which it occurred, likely due to the partial
burial (i.e., desolvation) of a charged residue upon binding (Fig-
ure 4D). However, the G97D mutation resulted in the formation of
a new internal hydrogen bond (HB) within the CDR3a loop to T99
(S99 in the WT 1G4 TCR), relative to the WT 1G4 TCR. This muta-
tion might help to rigidify and preorganize the CDR loop, and be
compensated for by the S96L and S99T mutations introduced along-
side. Furthermore, the S96L and S99T mutations likely benefit from a
more rigid/preorganized CDR loop, as this would allow for stronger
and more persistent interactions with the pHLA.
Further analysis of the impact of CDR3amutations suggested a bene-
ficial knock-on effect for HLA residue R65 and CDR2b residue D54,
which form a salt-bridge with one another, as all CDR3a mutated
aeTCRs formed an increased average number of HBs between the
TCR and R65 (Table S5). For the 1G4 aeTCR b chains, the substitu-
tion of the methyl side chain of A50 for a larger hydrophobic side
chain (A50V or A50I) in CDR2b was primarily responsible for the
increased binding affinity. Furthermore, the G49A mutation (seen
only in 1G4_c58c61) further increased the favorability toward bind-
ing, which contrasted with the more polar G49S mutation in the
1G4_c49c50 and 1G4_c58c62 aeTCRs (Figures 4E and 4F). CDR3b
loop mutations that increased affinity were largely mediated through
indirect effects, i.e., by increasing the favorability toward binding of
the CDR1b loop residue E28 (Figure 4G). This improvement in
E28 (seen only in TCRs with CDR3b loop mutations) was likely the
result of increased preorganization of E28 for binding through anMolecular Therapy: Oncolytics Vol. 18 September 2020 447
Figure 3. Changes in the Energetic Footprint
between WT TCRs and aeTCRs
(A) Experimental versus computational DDG values ob-
tained from our MMGBSA calculations for all TCR-pHLA
systems studied. Error bars plotted are the standard de-
viation obtained from the 25 replicas performed per com-
plex. (B) For all TCR-pHLA complexes, the HLA (top) and
TCR (bottom) structures are plotted as surfaces with the
peptide shown in both structures as ball and stick repre-
sentations. All plots are color mapped according to the
MMGBSA per residue decomposition results, going from
blue (favorable binding) towhite (neutral) to red (unfavorable
binding) with the WT TCR-pHLA complex on the left, and
the D (ae-WT) on the right for each system. Separate
scaling is used for each of the four sets of TCRs studied as
indicated by the color bars below each group (kcal mol1).
All pHLA and TCR structures are shown in the same
orientation, such that the peptide N terminus is left and the
C terminus is right. Several mutations sites are indicated on
the aeTCR variants (purple labels, CDRamutations; green
labels, CDRb mutations). For brevity only one 1G4 aeTCR
is shown. All others are shown in Figure S3.
Molecular Therapy: Oncolyticsincreased strength HB between the side chain carboxyl group and the
backbone of residue V/L94 (average HB occupancy in WT and
1G4_c49c50 simulations was between 0.50 and 0.56, compared to
1G4_c5c1, 1G4_c58c62, and 1G4_c58c61 where it was between
0.83 and 0.86).
All differences in sequence between the A6 TCR and A6_c134 aeTCR
occurred on the CDR3b loop (A99M, G100S, G101A, and R102Q),
and prior structural analysis suggested that the increased affinity
was due to a greater number of contacts between the TCR and
pHLA.27 Our binding energy decomposition analysis indicated that
mutations A99M and G100S were primarily responsible for the
enhanced affinity (Figures 5A and 5B), and in line with the prior
structural characterization, we observed an increase in the total
average number of contacts made between the TCR and the pHLA448 Molecular Therapy: Oncolytics Vol. 18 September 2020residues that sit below the CDR3b loop residues
A99M and G100S (Table S6).
For the DMF5 and DMF5_YW TCRs, two point
mutations designed in silico (D26Y on CDR1a
and L98W on CDR3b) gave rise to an approxi-
mate 400-fold enhancement in affinity.23 Anal-
ysisof the effectof theD26Ymutation (Figure5C)
suggested that the mutation was directly favor-
able, as well as enhancing the binding to K66
on HLA through the formation of a HB. In the
case of L98W (Figure 5D), the burial of a large ar-
omatic residue led to increased contribution to
the binding affinity.
For the MEL5_a24b17 aeTCR, a total of 19 mu-
tations (with 17 of these on TCR paratope) gaverise to the approximate 30,000-fold increase in affinity, which was
found to be primarily entropically driven.34 Consistent with this,
our simulation analysis indicated that several of the most favorable
mutations (CDRaD27F and CDRbG52P and I53F) increased the to-
tal amount of buried hydrophobic content at the binding interface.
This is likely an entropically favorable process due to the expulsion
of ordered water molecules that typically surround these hydrophobic
or aromatic groups upon binding. The only mutation that showed a
large negative effect on the binding energy was V93D CDR3a (Fig-
ures 5E and 5G). This mutation, however, results in a new interloop
HB with R96 (K96 in the WT MEL5 TCR). Similar to the G97D mu-
tation observed in some of the 1G4 eaTCRs, the mutation might play
a role in rigidifying the apo-loop (reducing the entropic penalty to-
ward binding), but also likely strengthens neighboring interactions,
through preorganization of the loop toward its bound conformation.
Figure 4. The 1G4 aeTCRs Show Largely Additive Energetic Effects upon Affinity Enhancement
(A) Per-residue DG differences as obtained from MMGBSA analysis between the aeTCR variants and 1G4 TCRs (i.e., DDG), with positions mutated indicated throughout in
red. DDG differences between the 1G4 TCR and aeTCRs are colored blue when %0.5 kcal mol–1 (favorable for binding) and red when >0.5 kcal mol–1 (unfavorable for
binding), with values in between colored green. (B–G) Color mapping of the above per residue DDG values onto all carbon atoms of the aeTCRs (with the 1G4 TCR structure
shown in green for reference). Color mapping is performed from blue to white to red, with blue indicating a favorable change and red indicating an unfavorable change for the
aeTCRs. Figures are divided to focus on the different regions of the TCR subjected to affinity maturation (CDR2a, CDR3a, CDR2b, and CDR3b), and subdivided when
mutations are not consistent between aeTCRs. (B) 1G4_c58c61/2, CDR2a; (C) 1G4_c49c50, CDR2a; (D) 1G4_c5c1 + 1G4_c58c61/2, CDR3a; (E) 1G4_c49c50 +
1G4_c58c62, CDR2b; (F) 1G4_c5c1 + 1G4_c58c61, CDR2b; and (G) 1G4_c5c1 + 1G4_c58c61/2, CDR3b. (1G4_c58c61/2 means that both 1G4_c58c61 and
1G4_c58c62 TCRs are shown).
www.moleculartherapy.org
Molecular Therapy: Oncolytics Vol. 18 September 2020 449
Figure 5. Changes in Energetics at the TCR-pHLA Interface upon Affinity Enhancement of the A6, DMF5, and MEL5 TCRs
(A) Per-residue DG differences as obtained from MMGBSA analysis between the A6, DMF5, and MEL5 derived aeTCR variants and their counterpart WT TCRs (i.e., DDG),
with positionsmutated indicated throughout in red.DDG differences between theWT TCR and aeTCR pair are colored blue when%0.5 kcal mol–1 (favorable for aeTCRs) and
red when 0.5 kcal mol–1 (unfavorable for aeTCRs), with all values in-between colored green. (B–G) Color mapping of the above per residue DDG values onto all carbon atoms
of the aeTCRs (with theWT TCR structure shown in green for reference). Color mapping is performed from blue towhite to red, with blue indicating a favorable change and red
indicating an unfavorable change for the aeTCRs, respectively. Figures are divided up to show the regions which show the major changes upon affinity maturation. (B)
A6_c134, CDR3b; (C) DMF5_YW, CDR1a; (D) DMF5_YW, CDR3b; (E) MEL5_a24b17, CDR2b; (F) MEL5_a24b17, CDR2b; and (G) MEL5_a24b17, CDR1a and CDR3a.
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www.moleculartherapy.orgInterestingly, of the 19 mutations present, only 9 showed substantial
energetic differences. Of the remaining 10 mutations, two positions
(CDR1a R28L and CDR3b T100M) made direct and favorable inter-
actions with the pHLA but were predicted to have similar strength in
both the MEL5 TCR and the MEL5_a24b17 aeTCR. The other eight
mutations did not make direct contact with the pHLA, some being
located within the ab framework interface, and may thus be involved
in regulating the flexibility, stability, and/or conformational sampling
of the TCR, and therefore indirectly alter the binding affinity.
Affinity-Enhancing Mutations Can Lead to Reductions in
Flexibility
The introduction of mutations to enhance affinity could also lead to
the rigidification of the TCR and/or TCR-pHLA complex, particu-
larly as some aeTCR residues have been positively selected that are
not involved in directly binding pHLA, and instead form inter-chain
contacts; e.g., stabilization of 1G4 TCR residue E28 (Figure 4G). To
examine this, we calculated the changes in root mean square fluctua-
tion (DRMSF) upon affinity enhancement from our MD simulations
of the TCRs in their apo (unbound) and pHLA-bound states (Figures
6A and 6B). For the 1G4 aeTCRs, we observed a decrease in the flex-
ibility of the CDR3a loop for the three variants that contained muta-
tions in this loop (1G4_c5c1, 1G4_c58c61, and 1G4_c58c62) (Fig-
ure 6A; Figure S4). Consistent with our energetic analysis, this
increase in rigidity could be rationalized by the substitution of a
glycine residue for a more conformationally restricted amino acid
(G97D). Furthermore, the carboxyl side chain of this mutated residue
was able to form an interloop HB with T99 (S99 in theWT IG4 TCR),
which could further rigidify the loop. An increase in the flexibility of
the HV4 a loop was observed for TCR variants 1G4_c49c50,
1G4_c58c62, and 1G4_c58c61, which was likely induced by muta-
tions made in the CDR2a loop given the proximity between these
two loops (Figure 6C).
For the MEL5_a24b17 aeTCR, DRMSFs indicated that the CDR1a,
CDR3a, and CDR2b loops at the TCR binding interface changed
significantly upon affinity enhancement (Figure 6B; Figure S5). We
note that both the positive and negative changes observed for the
CDR2b loop (Figure 6B) are likely the result of the large-scale rear-
rangement of this loop upon affinity enhancement.34 Consistent
with our observations from the energetic analysis, the increased rigid-
ity observed in both the apo and pHLA-bound forms of the CDR3a
loop was likely induced by the formation of a new interloop HB be-
tween the side chain of D93 (V93 in the WT MEL5 TCR) and R96
(K96 in the WT MEL5 TCR). In contrast, the CDR1a was only
observed to be more rigid in the pHLA-bound form, suggesting
increased rigidity of the loop was the result of stronger interactions
with the pHLA in MEL5_a24b17 over MEL5. Prior thermodynamic
analysis of the MEL5_a24b17 aeTCR demonstrated an improvement
in the entropy term of the binding free energy upon affinity matura-
tion compared to MEL5 (from a TDS of 8.3 kcal mol1 to
18.1 kcal mol1).34 The DRMSF data discussed above suggest that
this favorable effect was likely not primarily driven through changes
in rigidity, but instead through an improved solvation entropy contri-bution. The A6 TCR and A6_c134 aeTCR demonstrated no substan-
tial changes in flexibility for both the apo and pHLA-bound simula-
tions (Figure 6B; Figure S6). The DMF5 aeTCR showed a reduction in
the flexibility of the CDR1a and neighboring CDR2a and HVa loops
in the pHLA-bound simulations (Figure 6B; Figure S7). This local
reduction in mobility was likely induced by the HB between Y26 in
the CDR1a loop and K66 on the HLA, which is present only in the
aeTCR.
DISCUSSION
Recent progress in IO has placed treatments such as CAR-T and
checkpoint inhibitors firmly in the scientific and media spotlight.
These advances have contributed to the development of novel classes
of drugs, including soluble bispecific T cell engagers that can target
pHLA, as the next generation of cancer IOs.35 We, and others, have
previously demonstrated that it is possible to engineer the natural re-
ceptor for pHLA, the TCR, to overcome some of the limitations of the
weak natural binding affinity that could limit its use as a soluble ther-
apeutic.3,20–24 However, how these engineering approaches modulate
the natural binding characteristics of thymically selected TCRs is
poorly understood. Indeed, previous evidence has shown that
T cells engineered with even moderately affinity-enhanced TCRs
can cause off-target toxicities through, for example, molecular mim-
icry of self-antigens.36,37 Additionally, it has been shown that interac-
tions between the TCR b chain and pHLA can be altered by differen-
tial TCR a chain pairing independently of direct TCR a chain-pHLA
contacts, suggesting that the TCRVa-Vb interface can indirectly in-
fluence TCR specificity.38 Thus, the molecular rules that govern affin-
ity maturation of TCRs have strong implications for the design of
these molecules as efficacious and safe drugs for cancer treatment.
We used structural analysis, MD simulations, and free energy calcu-
lations to comprehensively characterize previously published aeTCRs
and solved the structure of a new enhanced affinity TCR-pHLA com-
plex to add to these datasets. These data demonstrate that aeTCRs
preserve a native-like TCR binding geometry but achieve affinity
enhancement via a range of different energetic mechanisms. More-
over, our free energy calculations reproduce the experimental affinity
relationships for all cases studied herein. This demonstrates that
atomistic simulations can be used to characterize the “energetic foot-
print” of different aeTCRs, allowing comparison with their thymically
selected WT TCR counterparts. This approach could be used as an in
silico assay to “filter” potential therapeutic TCR candidates and direct
intelligent engineering, to complement in vitro experimental speci-
ficity/safety validation.
Previously, studies have revealed that aeTCRs can use a range of
structural mechanisms during binding. For instance, the A6_c134
aeTCR was characterized by new peptide contacts driven directly
through mutated residues;27 the 1G4_c49c50 aeTCR bound via new
HLA interactions mediated by CDR2 loop mutations;2 the
MEL5_a24b17 aeTCR bound via an energetically favorable entropic
mechanism driven mainly by new HLA contacts;34 and the
DMF5_YW TCR bound almost identically to its WT counterpartMolecular Therapy: Oncolytics Vol. 18 September 2020 451
Figure 6. Differences in Flexibility between the aeTCRs Variable Regions and Their Counterpart WT TCRs
(A) DRMSF values (aeTCR variant RMSF-WT 1G4 TCR RMSF) for the 1G4-derived aeTCRs, with the top panels corresponding to the CDRa and CDRb of the apo TCRs, and
bottom panels corresponding to CDRa and CDRb of the TCRs in complex with pHLA. (B) DRMSF values (aeTCR variant RMSF-WT TCR RMSF) for the MEL5-, DMF5-, and
A6-derived aeTCRs, with top panels corresponding to the CDRa and CDRb of the apo TCRs, and bottom panels corresponding to CDRa and CDRb of the TCRs in complex
with pHLA. A more negative DRMSF value indicates increased rigidity for the aeTCR variant relative to the WT TCR. The points toward the bottom of each graph indicate
residues with significantly different DRMSF values as determined by a two-sample t test (p < 0.05). The numbers boxed in red represent regions of each aeTCR that increase
rigidity compared to the WT TCRs in the pHLA bound form. Complete RMSF plots for all TCRs simulated are provided in Figures S4–S7. (C) For each region of the aeTCRs
where increased rigidity compared to the WT TCRs in pHLA bound form was observed (marked by numbers in red boxes), the corresponding CDR or HV4 loop of the TCR is
shown (as cartoon colored in accordance with A and B) with mutations fromWT TCR to aeTCR labeled (shown as red sticks). Black arrows show which regions of the TCR-
pHLA complex are near each loop, to provide a potential mechanism for the increases in rigidity detected.
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action dynamics.23 Despite the differential mechanisms, aeTCRs can
maintain peptide specificity independently of the structural mecha-
nisms guiding their interactions with pHLA.29 Indeed, it has recently
been shown that, using structure-guided approaches, it is possible to
improve TCR specificity for a given antigen.20,39 In this study, our
simulations and binding energy calculations showed that the mecha-
nisms underpinning the ability of the aeTCRs to bind to pHLA with
enhanced affinity are complex, with indirect and compensatory ef-
fects being common. For example, the 1G4 aeTCRs were character-
ized by energetically favorable effects mediated by direct/indirect pep-
tide and/or HLA interactions with multiple CDR loops, while
energetically favorable contributions for the A6_c134 aeTCR were
driven almost exclusively through the mutated residues in the
CDR3b loop. Furthermore, our analyses indicated that the introduc-
tion and burial of large aromatic or hydrophobic side chains at the
HLA interface are common in affinity enhancement. This observation
ties in with the fact that the most commonly identified residues in
protein-protein binding sites are Trp, Met, and Phe.40 Finally, in
both the 1G4 TCR and MEL5 TCR systems, we observed mutations
that formed new interloop HBs, resulting in the rigidification of the
respective CDR loops of those TCRs (in both the apo and pHLA-
bound form). Thus, rationally designing mutations that preorganize
the CDR loops for a given antigen may be beneficial for TCR-
pHLA affinity.
The data presented raise some interesting biological questions con-
cerning the nature of TCR selection in the thymus, as they demon-
strate that the natural TCR scaffold and binding mode is compatible
with supra-physiological affinity enhancements.3,6 If this is the case,
why have no natural TCRs ever been detected with such strong affin-
ities? A possible reason could be that the introduction of large aro-
matic or hydrophobic side chains at the HLA interface, as we
observed for the majority of the aeTCRs investigated in this study,
could lead to self-reactivity when the TCR is expressed in the context
of the T cell surface. Indeed, a recent study demonstrated an enrich-
ment in TCRs with hydrophobic residues in the CDR3 loops in auto-
immunity.41 Additionally, a number of reports have shown that TCRs
binding to autoantigens can utilize aromatic residues to directly
engage with the autoantigen.42–44 Thus, natural TCRs with a CDR
loop enrichment in residues with large aromatic or hydrophobic
side chains (that could have the potential for strong affinity binding)
might be deleted in the thymus through negative selection. Finally,
weak TCR affinity may enable T cells to rapidly disengage from target
cells to allow them to effectively penetrate tissues. This may
contribute to the observation that stronger affinity CAR-T cells
have a limited ability to penetrate solid tumors.17
Our biomolecular simulations successfully ranked the affinity-
enhanced variants and identified some commonly adopted strategies
for affinity enhancement. The approaches used in this study therefore
show early promise for aiding the rational design and implementation
of TCR-based therapies. However, prediction of affinity-enhancing
TCR mutations might be challenging because the TCR-pHLA systemuses a broader andmore energetically balanced bindingmode than do
other immune-related protein-protein interactions (e.g., antibodies,
or therapeutic peptides18,19,45), resulting in a complex interconnected
interface.45 Furthermore, the peptide repertoire is so diverse that
there are likely no fully universal strategies that can be used to affinity
enhance TCRs. In any case, it is likely that computational tools will sit
alongside other experimental approaches to ensure that therapeuti-
cally deployed aeTCRs maintain peptide selectivity relative to their
WT parent TCR.46
MATERIALS AND METHODS
Cloning, Expression, and Refolding of Proteins
The TCR a and TCR b chains, as well as the HLA class I a chains
(tagged and not tagged with a biotinylation sequence) and b2-micro-
globulin (b2m) sequences, were cloned, expressed, and refolded as
previously described.47
Protein Crystallization and Structure Determination
Crystals were grown at 18C by vapor diffusion via the sitting drop
technique. All crystallization screening and optimization experi-
ments were completed with an Art-Robbins Phoenix dispensing
robot (Alpha Biotech, UK). 200 nL of 10–15 mg/mL TCR-pHLA
complex mixed at a 1:1 molar ratio was added to 200 nL of reservoir
solution. Intelli-Plates were then sealed and incubated at 18C in a
crystallization incubator (RuMed, Rubarth Apperate, Germany) and
analyzed for crystal formation using the Rock Imager 2 (Formula-
trix, Bedford, MA, USA). Crystals selected for further analysis
were cryoprotected with ethylene glycol to 25% and then flash
cooled in liquid nitrogen in Litho loops (Molecular Dimensions,
UK). For a24b17-A2-EAA, optimal crystals were obtained in
TOPS48 with 0.1 M HEPES (pH 7.5), 0.2 M ammonium sulfate,
15% polyethylene glycol (PEG) 4000, and 8.7% glycerol. Diffraction
data were collected at several different beamlines at the Diamond
Light Source (Oxford, UK) using a Pilatus 2M detector, a QADSC
detector, or a Rayonix detector. Using a rotation method, 400
frames were recorded, each covering 0.5 of rotation. Reflection in-
tensities were estimated with the XIA2 package,49,50 and the data
were scaled, reduced, and analyzed with SCALA and the CCP4
package.51 The TCR-pHLA complex structures were solved with
molecular replacement using PHASER.52 The model sequences
were adjusted with COOT53 and the models refined with
REFMAC5. The accession code for a24b17-A2-EAA is PDB:
6TMO.
MD Simulations and Free Energy Calculations
The following is a short overview of the computational methods used
herein; a detailed description is provided in the Supplemental Mate-
rials and Methods. X-ray crystal structures obtained from multiple
studies were used as the starting point for MD simulations of TCRs
in both their apo and pHLA-bound states (Table 1; Tables S2 and
S3). Following structure preparation, all systems were solvated in a
truncated octahedral water box (retaining any crystal waters) large
enough to ensure that all protein atoms were at least 10 Å away
from the box boundary. Simulations were performed usingMolecular Therapy: Oncolytics Vol. 18 September 2020 453
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to describe protein and water molecules, respectively. In order to pre-
pare for production-quality MD simulations in the NPT ensemble (at
300 K and 1 atm), we used a previously described minimization, heat-
ing, and equilibration procedure.56 Subsequently, each system was
subjected to 10 replicas of 100-ns-long production MD simulations,
with the last 90 ns of each run used for analysis with the software
package CPPTRAJ.57 MMGBSA calculations were performed using
MMPBSA.py.MPI,32 using a protocol (described below) that has pre-
viously been shown to provide converged and accurate relative bind-
ing free energies for pHLA binding.58 We performed 25 replicas of 4-
ns-long MD simulations per system (separate to the above described
100-ns-long simulations). From each replica, 300 equally spaced
snapshots were extracted from the last 3 ns of each MD simulation
and subjected to MMGBSA calculations. MMGBSA calculations
used the GB-Neck2 (i.e., igb = 8) solvation model and an implicit
salt concentration of 150 mM. The obtained results were decomposed
into their per-residue contributions to the total binding free energy,
with the values obtained used to calculate the differences between
the WT and aeTCRs.
Detailed methodology is described in the Supplemental Materials and
Methods.SUPPLEMENTAL INFORMATION
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